Cialis, Ambien CR top sites driving prescription requests, study says

Share this article:
Lilly Icos’ Cialis was identified as the pharmaceutical product site with the highest percent of visitors requesting a prescription after visiting, a new study says. Cialis was followed by Pfizer’s Viagra, AstraZeneca’s Nexium, Sepracor’s Lunesta and Sanofi-Aventis’ Allegra respectively, according to the results of the study conducted by market research firm Manhattan Research. The study, titled ePharma Consumer v6.0: The Future of Integrated DTC Marketing, provides data on over 100 pharmaceutical product sites and consumer actions as polled from 4,965 US adults. The Manhattan Research study further identified Sanofi-Aventis’ Ambien CR Web site as the top Rx product site driving prescription requests after visiting the site by prescription volume. Ambien CR was followed by Sanofi-Aventis’ Allegra, GlaxoSmithKline’s Wellbutrin XL, Sepracor’s Lunesta and AstraZeneca’s Lunesta respectively. Further details of the ePharma Consumer v6.0 study will be made available during a Webinar being offered by Manhattan Research today.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...